Menopause and vasomotor symptoms (hot flashes): cross-border specialty drug access for international patients

Quick orientation

An estimated 60 to 80 percent of women experience vasomotor symptoms during the menopausal transition. Moderate to severe symptoms affect approximately 30 percent of women.

Typical age of onset. Typically between ages 45 and 55. Symptoms can persist for years.

Severity tiers. Severity ranges from mild and self-limited to severely disruptive of sleep and quality of life.

Why specialty drugs for Menopause and vasomotor symptoms (hot flashes) are hard to access internationally

Veozah (fezolinetant) and Lynkuet (elinzanetant) are the first neurokinin receptor antagonists approved for moderate to severe hot flashes. International registration is in early stages. Many women prefer non-hormonal options where contraindicated.

Treatments approved by the FDA

• Veozah (fezolinetant) — FDA approval: 2023. Mechanism: Neurokinin 3 receptor antagonist. Route: Oral once daily. US WAC ballpark: Approximately USD 8,000 per year. Country pricing: Oman.

Cross-border pathways used for Menopause and vasomotor symptoms (hot flashes)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Personal Import Scheme
• Cross-border Prescription

What your physician needs to know

• Confirm moderate to severe vasomotor symptoms.
• Document hormone replacement therapy contraindications or patient preference for non-hormonal therapy.
• Liver function baseline and monitoring per label.
• Gynecologist or primary care co-management.

Common questions

Is Veozah a hormone?

No. It is a non-hormonal neurokinin receptor antagonist.

Is it available in my country?

International rollout is in progress. We confirm by destination.

How long until symptom relief?

Many patients see meaningful improvement within 4 weeks.

Are there liver concerns?

Periodic liver function tests are recommended per label.

What documents are required?

Treating physician's prescription, baseline liver function, and symptom documentation.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Menopause and vasomotor symptoms (hot flashes), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Menopause and vasomotor symptoms (hot flashes)

Reserved for you.